Founder & CEO, Brud
- Artificial Intelligence (AI)
- Innovation and Technology
- Health Care Sciences
- Diversity and Inclusion
Audience & Industry
- The Technology Industry
- The Health Care Industry
- The Professional Services Industry
Creating next-generation medicines from human genomics.
Alice Zhang is CEO and Co-Founder of Verge Genomics, a new type of therapeutics company that takes a patient data-driven approach to unlock a whole spectrum of therapies that have escaped traditional drug discovery, beginning with diseases where patients need solutions the most: neurodegenerative disease. She has been named a San Francisco Business Times’ 40 Under 40, MIT Technology Review’s Innovator Under 35, Forbes 30 Under 30 Featured Honoree, and featured in Forbes 2021 AI50: America's Most Promising AI Companies. Prior to Verge, she spent seven years at the forefront of systems biology research at the National Cancer Institute, the Lewis-Sigler Institute for Integrative Genomics at Princeton University, and UCLA. She spent five years in the UCLA-Caltech MD/PhD program, where she helped author several papers on gene networks involved in neuroregeneration. Alice received her bachelor’s degree from Princeton University in Molecular Biology and was a recipient of the prestigious Paul & Daisy Soros Fellowship for New Americans. In her spare time, Alice also is an angel investor and advisor for startups at the intersection of technology and biology.
Alice Zhang on Using AI to Transform Finding a Cure
Alice Zhang on Academic Discovery to Startup
Alice Zhang's Speech Topics
Insights with Alice Zhang
Alice Zhang shares insights into disrupting the system, treating the untreatable with AI, therapeutics, life sciences, biotech, pharma, CNS and neurodegeneration, being a young female founder and CEO, working with VC and investors, diversity and inclusion, and start up related challenges.